Medicenna (MDNA) | Stock Overview & Key Data
Medicenna Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $3.64 on February 24, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Medicenna
MDNA
|
N/A | N/A | N/A | N/A | N/A | N/A | 196.43% | -17.00% | -17.00% | -17.00% | -17.00% | -17.00% |
|
Vertex
VRTX
|
109.45B Large-cap | 1.69% | 3.09% | -3.36% | -1.15% | -0.37% | -2.31% | 27.89% | 136.85% | 413.01% | 888.51% | 1,245.83% |
|
Regeneron
REGN
|
80.98B Large-cap | 0.60% | -11.93% | -18.75% | -18.29% | -20.78% | 15.66% | -21.83% | 13.80% | 72.82% | 1,033.17% | 4,804.97% |
|
Alnylam
ALNY
|
41.87B Large-cap | -1.49% | 0.29% | -9.76% | -26.49% | -28.08% | -8.16% | 40.32% | 59.90% | 405.36% | 3,032.34% | 1,907.45% |
|
Royalty Pharma plc
RPRX
|
29.43B Large-cap | -1.08% | 2.69% | 17.72% | 40.85% | 39.66% | 57.49% | 72.01% | 24.65% | 11.98% | 11.98% | 11.98% |
|
Insmed
INSM
|
31.05B Large-cap | 3.49% | -10.70% | -32.60% | -50.51% | -44.98% | -0.89% | 389.25% | 236.25% | 934.36% | 717.46% | 614.23% |
Ownership & Short Interest
Calculate Your Medicenna Investment Returns
Long-Term Investment Performance Analysis
Medicenna stock price in Nov 2017 was $2.00, A $1,000.00 lump sum investment in Medicenna made 7 years ago would be worth approximately $80.00 today, representing a negative return of -92.00%. This translates to an annualized return (CAGR) of -28.27%.
7 Years 7 Months Investment Scenario (Nov 2017 - Jun 2025)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is MDNA's 52-week high and low?
- In the last 52 weeks, Medicenna reached a high of $2.17 (on June 2, 2024) and a low of $0.15 (on January 16, 2025).
- What is the market cap and P/E ratio for MDNA?
- Curious about Medicenna's size and valuation? Its market capitalization stands at N/A. When it comes to valuation, the P/E ratio (trailing twelve months) is -0.98, and the forward P/E (looking ahead) is -0.75.
- Does MDNA pay dividends? If so, what's the yield?
- As for dividends, Medicenna isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Medicenna's main competitors or similar companies to consider before investing?
When looking at Medicenna, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX109.45B Healthcare Biotechnology -2.31% 27.89% Regeneron
REGN80.98B Healthcare Biotechnology 15.66% -21.83% Alnylam
ALNY41.87B Healthcare Biotechnology -8.16% 40.32% Royalty Pharma plc
RPRX29.43B Healthcare Biotechnology 57.49% 72.01% Insmed
INSM31.05B Healthcare Biotechnology -0.89% 389.25% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Medicenna Therapeutics Corp.? (e.g., ROE, Debt/Equity)
- To get a sense of Medicenna's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -34.08%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for MDNA?
- Looking at Medicenna's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of MDNA stock is held by insiders and institutions?
- Wondering who owns Medicenna stock? Company insiders (like executives and directors) hold about N/A of the shares, while institutional investors (such as mutual funds and pension funds) own approximately N/A.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.